In a recent study led by Leigh Turner, PhD, it was revealed that stem cell and exosome treatments are being marketed to patients suffering from long COVID by 36 businesses. These treatments, boasting claims of symptomatic relief, immune boosting, acute COVID infection treatment, and prevention of COVID, have an average cost of $11,322. However, despite their prevalence, these treatments lack extensive scientific evidence and pose potential risks, including serious injury and financial scams. This raises the need for stricter regulation by the Food and Drug Administration (FDA) and the Federal Trade Commission (FTC).

According to the study, the majority of these businesses offering stem cell and exosome treatments for long COVID are based in the U.S. and Mexico. The cost of these therapies ranges from $2,950 to $25,000. Despite the FDA and FTC issuing warning letters to such companies, the marketplace remains vast and largely unregulated. It is noteworthy that long COVID patients, in their desperation for relief, can easily fall prey to entities making appealing therapeutic claims without solid scientific evidence.

While the use of stem cell and exosome treatments for long COVID remains controversial, research has highlighted the potential of Mesenchymal stem cell-derived exosomes (MSC-Exos) in the treatment of lung diseases. They are considered a more stable and safer option than traditional cell therapies. MSC-Exos deliver non-coding RNAs (ncRNAs) to communicate with target cells, inhibiting inflammatory factors, reducing oxidative stress, promoting normal lung cell proliferation, and reducing apoptosis. Some researchers are exploring the detailed mechanisms of MSC-Exos in the clinical treatment of lung disease by developing standardized culture, isolation, purification, and administration strategies.

Its important to note that the link between stem cell treatments and COVID-19 isnt entirely new. A study conducted during the recent COVID-19 outbreak in China revealed that pediatric patients who had received hematopoietic stem cell transplants were more susceptible to COVID-19 infection. This vulnerability was particularly high in recipients over 100 days post-transplant. This study, while not directly connected to the stem cell and exosome treatments for long COVID, does provide some insight into the interaction between stem cell treatments and COVID-19.

While there are ongoing clinical trials and research exploring the use of stem cell and exosome treatments for long COVID, the current lack of substantial scientific evidence calls for caution. Potential benefits for managing long-term symptoms of COVID-19 are promising, but more rigorous scientific studies are needed to confirm these benefits and to understand the risks involved.

Given the potentially serious risks and the high cost of these treatments, there is an urgent need for stricter regulations to prevent financial scams and to ensure patient safety. It is crucial that the FDA and FTC take more robust actions to regulate this marketplace. Until then, patients and healthcare professionals should approach such treatments with caution, critically evaluating claims and seeking treatments that are backed by solid scientific evidence.

View original post here:
The Risks of Stem Cell and Exosome Treatments for Long COVID: A Call for Stricter Regulations - Medriva